The CMA imposed fines of more than £100 million on Advanz Ltd. after it had excessively inflated the price of thyroid tablets for more than eight years, to the detriment of patients and the National Health Service (NHS).[1]

A previous investigation by the CMA reveals that in the period from 2009 to 2017, Advanz Ltd. charged unfair prices for the supply of liothyronine tablets used to treat thyroid hormone deficiency. Advanz Ltd. was able to do so because there was little or no competition in the sale of liothyronine tablets. The investigation was part of the CMA’s ongoing work in the pharmaceutical sector.

[1] CMA press release, ‘CMA fines pharma firm over pricing of crucial thyroid drug’, 29 July 2021.